Akari Therapeutics Plc Shares outstanding
What is the Shares outstanding of Akari Therapeutics Plc?
The Shares outstanding of Akari Therapeutics Plc is 12.145M
What is the definition of Shares outstanding?
Shares outstanding are all the shares of a corporation or of a financial asset that have been authorized, issued and purchased by investors and are held by them.
= issued shares - treasury shares
Shares outstanding includes all stock held by investors including both common shares held by the public and restricted shares owned by the company's internal managements. Shares outstanding have rights and represent an ownership in the corporation by the person who holds the shares. They are distinguished from treasury shares, which are shares held by the corporation itself and have no exercisable rights. Shares outstanding plus treasury shares together amount to the number of issued shares.
Shares outstanding can be calculated as either basic or fully diluted. The basic count is the current number of shares. Dividend distributions and voting in the general meeting of shareholders are calculated according to this number. The fully diluted shares outstanding count, on the other hand, includes diluting securities, such as warrants, capital notes or convertibles. If the company has any diluting securities, this indicates the potential future increased number of shares outstanding. A company's market capitalization is calculated by multiplying the price of one of its shares by the total number outstanding shares a company has issued.
Shares outstanding of companies in the Health Care sector on NASDAQ compared to Akari Therapeutics Plc
What does Akari Therapeutics Plc do?
akari is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics to treat orphan autoimmune and inflammatory diseases. akari’s lead drug, coversin, a second-generation and potentially best-in-class complement inhibitor, acts on complement component-c5, preventing release of c5a and formation of c5b – 9 (also known as the membrane attack complex or mac). coversin is a recombinant small protein (16,740 da) derived from a native protein discovered in the saliva of the ornithodoros moubata tick, where it modulates the host immune system to allow the parasite to feed without alerting the host to its presence or provoking an immune response.
Companies with shares outstanding similar to Akari Therapeutics Plc
- Credit Acceptance has Shares outstanding of 12.111M
- Stratec SE has Shares outstanding of 12.128M
- Immunome has Shares outstanding of 12.129M
- Swaraj Engines has Shares outstanding of 12.134M
- Swaraj Engines has Shares outstanding of 12.141M
- Le Tanneur & Cie Societe anonyme has Shares outstanding of 12.144M
- Akari Therapeutics Plc has Shares outstanding of 12.145M
- S&U Plc has Shares outstanding of 12.151M
- John Hancock Hedged equity & Income Fund has Shares outstanding of 12.151M
- Gandhi Special Tubes has Shares outstanding of 12.152M
- Emmis Corp has Shares outstanding of 12.157M
- Prime People Plc has Shares outstanding of 12.157M
- PermRock Royalty Trust has Shares outstanding of 12.166M